PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AbbVie and J&J withdraw two cancer approvals for a blockbuster drug

AbbVie announced its plans to voluntarily withdraw the FDA’s accelerated approval for Imbruvica in two blood cancer indications — mantle cell lymphoma (MCL) and refractory marginal zone lymphoma (MZL).  Imbruvica is an oral Bruton’s tyrosine kinase (BTK) inhibitor that was first approved in 2013. Initially developed by Pharmacyclics, it was acquired by AbbVie in 2015 and jointly marketed with Johnson & Johnson. The drug has had an extensive clinical program with dozens of studies evaluating its efficacy in a number of indications. It was most recently approved by the FDA for the treatment of patients aged one and older with chronic graft-versus-host disease, making it the first and only BTK drug available for pediatric patients. The drug was initially granted FDA approval for MCL and MZL based on the overall response rates observed in two phases 2 clinical trials under the accelerated approval pathway, but its continued approval was dependent on the demonstration of clinical benefits. The phase 3 SHINE study in previously untreated MCL and the phase 3 SELENE study in relapsed or refractory MZL served as confirmatory studies. Following a discussion with the companies regarding the study findings, the FDA recommended that the primary outcomes of phase 3 confirmatory trials for the indications were inadequate to justify conversion to full approval. In one of phase 3 confirmatory trials, Imbruvica met its primary endpoint of progression-free survival but was associated with increased adverse reactions when given in addition to chemotherapy. In the phase 3 SELENE study, which evaluated the drug as a treatment for relapsed MZL, Imbruvica did not meet its primary goal of progression-free survival.  In a recent statement, Roopal Thakkar, AbbVie’s senior vice president and chief medical officer said, “While we are disappointed in the outcome of the confirmatory trials for these indications, we remain confident in the benefit/risk profile of Imbruvica for patients living with multiple forms of blood cancer around the world.” This is not the first time that Imbruvica fails to impress for other cancer indications. In 2019, the treatment failed to show statistically significant improvement in progression-free survival (PFS) or overall survival in metastatic pancreatic cancer patients, compared with the combination of a placebo and two chemotherapy agents.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026